

**BEFORE THE
BOARD OF PHARMACY
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA**

In the Matter of the Accusation Against:

**SOUTHERN CALIFORNIA HEALTHCARE SYSTEMS, INC., DBA
SOUTHERN CALIFORNIA HOSPITAL AT CULVER CITY,**

**Hospital Pharmacy Permit No. HSP 51172 and
Sterile Compounding Permit No. LSC 100222;**

**JILL CHANG,
Pharmacist License No. RPH 66782;**

**AINSLIE HOI LI CHEUNG,
Pharmacist License No. RPH 64668; and**

**JACQUELINE HOANG VO,
Pharmacist License No. RPH 45816;**

Respondents

Agency Case No. 6647; OAH No. 2020040205

DECISION AND ORDER

The attached Stipulated Settlement and Disciplinary Order is hereby adopted by the Board of Pharmacy, Department of Consumer Affairs, as its Decision in this matter.

This Decision shall become effective at 5:00 p.m. on March 19, 2021.

It is so ORDERED on February 17, 2021.

BOARD OF PHARMACY
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA

A handwritten signature in black ink, appearing to read "Greg M. Lippe", written in a cursive style.

By

Greg Lippe
Board President

1 XAVIER BECERRA
Attorney General of California
2 ARMANDO ZAMBRANO
Supervising Deputy Attorney General
3 NANCY A. KAISER
Deputy Attorney General
4 State Bar No. 192083
300 So. Spring Street, Suite 1702
5 Los Angeles, CA 90013
Telephone: (213) 269-6320
6 Facsimile: (916) 731-2126
Attorneys for Complainant
7

8 **BEFORE THE**
9 **BOARD OF PHARMACY**
10 **DEPARTMENT OF CONSUMER AFFAIRS**
11 **STATE OF CALIFORNIA**

12 In the Matter of the Accusation Against:

13 **SOUTHERN CALIFORNIA**
14 **HEALTHCARE SYSTEMS, INC.,**
15 **DBA SOUTHERN CALIFORNIA**
16 **HOSPITAL AT CULVER CITY**
3828 Delmas Terrace
Culver City, CA 90232
Hospital Pharmacy Permit No. HSP 51172,

17 **SOUTHERN CALIFORNIA**
18 **HEALTHCARE SYSTEMS, INC.,**
19 **DBA SOUTHERN CALIFORNIA**
20 **HOSPITAL AT CULVER CITY**
3828 Delmas Terrace
Culver City, CA 90232
Sterile Compounding Permit No. LSC
100222,

21 **JILL CHANG**
22 **778 Flicker Ct.**
23 **Anaheim, CA 92807**
Pharmacist License No. RPH 66782,

24 **AINSLIE HOI LI CHEUNG**
25 **12837 Palisades Ct.**
26 **Poway, CA 92064**
Pharmacist License No. RPH 64668,

27 **and**
28

Case No. 6647

OAH No. 2020040205

**STIPULATED SETTLEMENT AND
DISCIPLINARY ORDER AS TO
AINSLIE HOI LI CHEUNG ONLY**

JACQUELINE HOANG VO
15757 McIntosh Ave.
Chino, CA 91708
Pharmacist License No. RPH 45816,

Respondents.

IT IS HEREBY STIPULATED AND AGREED by and between the parties to the above-entitled proceedings that the following matters are true:

PARTIES

1. Anne Sodergren (Complainant) is the Executive Officer of the Board of Pharmacy (Board). She brought this action solely in her official capacity and is represented in this matter by Xavier Becerra, Attorney General of the State of California, by Nancy A. Kaiser, Deputy Attorney General.

2. Respondent Ainslie Hoi Li Cheung (Respondent) is represented in this proceeding by attorney Luis Andre P. Vizcocho, whose address is: California Pharmacy Lawyers, 55 Cetus, 1st Floor, Irvine, CA 92618.

3. On or about September 30, 2010, the Board of Pharmacy issued Pharmacist License Number RPH 64668 to Ainslie Hoi Li Cheung (Respondent Cheung). The Pharmacist License was in full force and effect at all times relevant to the charges brought herein and will expire on December 31, 2021, unless renewed.

JURISDICTION

4. Accusation No. 6647 was filed before the Board, and is currently pending against Respondent. The Accusation and all other statutorily required documents were properly served on Respondent on October 2, 2019. Respondent timely filed his Notice of Defense contesting the Accusation.

5. A copy of Accusation No. 6647 is attached as exhibit A and incorporated herein by reference.

ADVISEMENT AND WAIVERS

6. Respondent has carefully read, fully discussed with counsel, and understands the charges and allegations in Accusation No. 6647. Respondent has also carefully read, fully

1 discussed with counsel, and understands the effects of this Stipulated Settlement and Disciplinary
2 Order.

3 7. Respondent is fully aware of his legal rights in this matter, including the right to a
4 hearing on the charges and allegations in the Accusation; the right to confront and cross-examine
5 the witnesses against them; the right to present evidence and to testify on his own behalf; the right
6 to the issuance of subpoenas to compel the attendance of witnesses and the production of
7 documents; the right to reconsideration and court review of an adverse decision; and all other
8 rights accorded by the California Administrative Procedure Act and other applicable laws.

9 8. Respondent voluntarily, knowingly, and intelligently waives and gives up each and
10 every right set forth above.

11 **CULPABILITY**

12 9. Respondent understands and agrees that the charges and allegations in Accusation
13 No. 6647, if proven at a hearing, constitute cause for imposing discipline upon her Pharmacist
14 License.

15 10. For the purpose of resolving the Accusation without the expense and uncertainty of
16 further proceedings, Respondent agrees that, at a hearing, Complainant could establish a factual
17 basis for the charges in the Accusation, and that Respondent hereby gives up his right to contest
18 those charges.

19 11. Respondent agrees that her Pharmacist License is subject to discipline and he agrees
20 to be bound by the Board's probationary terms as set forth in the Disciplinary Order below.

21 **CONTINGENCY**

22 12. This stipulation shall be subject to approval by the Board. Respondent understands
23 and agrees that counsel for Complainant and the staff of the Board may communicate directly
24 with the Board regarding this stipulation and settlement, without notice to or participation by
25 Respondent or his counsel. By signing the stipulation, Respondent understands and agrees that he
26 may not withdraw his agreement or seek to rescind the stipulation prior to the time the Board
27 considers and acts upon it. If the Board fails to adopt this stipulation as its Decision and Order,
28 the Stipulated Settlement and Disciplinary Order shall be of no force or effect, except for this

paragraph, it shall be inadmissible in any legal action between the parties, and the Board shall not be disqualified from further action by having considered this matter.

13. The parties understand and agree that Portable Document Format (PDF) and facsimile copies of this Stipulated Settlement and Disciplinary Order, including PDF and facsimile signatures thereto, shall have the same force and effect as the originals.

14. This Stipulated Settlement and Disciplinary Order is intended by the parties to be an integrated writing representing the complete, final, and exclusive embodiment of their agreement. It supersedes any and all prior or contemporaneous agreements, understandings, discussions, negotiations, and commitments (written or oral). This Stipulated Settlement and Disciplinary Order may not be altered, amended, modified, supplemented, or otherwise changed except by a writing executed by an authorized representative of each of the parties.

15. In consideration of the foregoing admissions and stipulations, the parties agree that the Board may, without further notice or formal proceeding, issue and enter the following Disciplinary Order:

DISCIPLINARY ORDER

IT IS HEREBY ORDERED that Pharmacist License Number RPH 64668 issued to Respondent Ainslie Hoi Li Cheung is revoked. However, the revocation is stayed and Respondent is placed on probation for eighteen (18) months on the following terms and conditions:

1. Obey All Laws

Respondent shall obey all state and federal laws and regulations.

Respondent shall report any of the following occurrences to the Board, in writing, within seventy- two (72) hours of such occurrence:

- an arrest or issuance of a criminal complaint for violation of any provision of the Pharmacy Law, state and federal food and drug laws, or state and federal controlled substances laws
- a plea of guilty, or nolo contendere, no contest, or similar, in any state or federal criminal proceeding to any criminal complaint, information or indictment

- a conviction of any crime
- the filing of a disciplinary pleading, issuance of a citation, or initiation of another administrative action filed by any state or federal agency which involves Respondent's license or which is related to the practice of pharmacy or the manufacturing, obtaining, handling, distributing, billing, or charging for any drug, device or controlled substance.

Failure to timely report such occurrence shall be considered a violation of probation.

2. Report to the Board

Respondent shall report to the Board quarterly, on a schedule as directed by the Board or its designee. The report shall be made either in person or in writing, as directed. Among other requirements, Respondent shall state in each report under penalty of perjury whether there has been compliance with all the terms and conditions of probation.

Failure to submit timely reports in a form as directed shall be considered a violation of probation. Any period(s) of delinquency in submission of reports as directed may be added to the total period of probation. Moreover, if the final probation report is not made as directed, probation shall be automatically extended until such time as the final report is made and accepted by the Board.

3. Interview with the Board

Upon receipt of reasonable prior notice, Respondent shall appear in person for interviews with the Board or its designee, at such intervals and locations as are determined by the Board or its designee. Failure to appear for any scheduled interview without prior notification to Board staff, or failure to appear for two (2) or more scheduled interviews with the Board or its designee during the period of probation, shall be considered a violation of probation.

4. Cooperate with Board Staff

Respondent shall timely cooperate with the Board's inspection program and with the Board's monitoring and investigation of Respondent's compliance with the terms and conditions of his probation, including but not limited to: timely responses to requests for information by Board staff; timely compliance with directives from Board staff regarding requirements of any

term or condition of probation; and timely completion of documentation pertaining to a term or condition of probation. Failure to timely cooperate shall be considered a violation of probation.

5. Continuing Education

Respondent shall provide evidence of efforts to maintain skill and knowledge as a pharmacist as directed by the Board or its designee.

6. Reporting of Employment and Notice to Employers

During the period of probation, Respondent shall notify all present and prospective employers of the decision in case number 6647 and the terms, conditions and restrictions imposed on Respondent by the decision, as follows:

Within thirty (30) days of the effective date of this decision, and within ten (10) days of undertaking any new employment, Respondent shall report to the Board in writing the name, physical address, and mailing address of each of his employer(s), and the name(s) and telephone number(s) of all of his direct supervisor(s), as well as any pharmacist(s)-in-charge, designated representative(s)-in-charge, responsible manager, or other compliance supervisor(s) and the work schedule, if known. Respondent shall also include the reason(s) for leaving the prior employment. Respondent shall sign and return to the Board a written consent authorizing the Board or its designee to communicate with all of Respondent's employer(s) and supervisor(s), and authorizing those employer(s) or supervisor(s) to communicate with the Board or its designee, concerning Respondent's work status, performance, and monitoring. Failure to comply with the requirements or deadlines of this condition shall be considered a violation of probation.

Within thirty (30) days of the effective date of this decision, and within fifteen (15) days of Respondent undertaking any new employment, Respondent shall cause (a) his direct supervisor, (b) his pharmacist-in-charge, designated representative-in-charge, responsible manager, or other compliance supervisor, and (c) the owner or owner representative of his employer, to report to the Board in writing acknowledging that the listed individual(s) has/have read the decision in case number 6647, and terms and conditions imposed thereby. If one person serves in more than one role described in (a), (b), or (c), the acknowledgment shall so state. It shall be the Respondent's responsibility to ensure that these acknowledgment(s) are timely submitted to the Board. In the

1 event of a change in the person(s) serving the role(s) described in (a), (b), or (c) during the term
2 of probation, Respondent shall cause the person(s) taking over the role(s) to report to the Board in
3 writing within fifteen (15) days of the change acknowledging that he or she has read the decision
4 in case number 6647, and the terms and conditions imposed thereby.

5 If Respondent works for or is employed by or through an employment service, Respondent
6 must notify the person(s) described in (a), (b), and (c) above at every his licensed by the Board of
7 the decision in case number 6647, and the terms and conditions imposed thereby in advance of
8 Respondent commencing work at such licensed his. A record of this notification must be
9 provided to the Board upon request.

10 Furthermore, within thirty (30) days of the effective date of this decision, and within fifteen
11 (15) days of Respondent undertaking any new employment by or through an employment service,
12 Respondent shall cause the person(s) described in (a), (b), and (c) above at the employment
13 service to report to the Board in writing acknowledging that he or she has read the decision in
14 case number, and the terms and conditions imposed thereby. It shall be Respondent's
15 responsibility to ensure that these acknowledgment(s) are timely submitted to the Board.

16 Failure to timely notify present or prospective employer(s) or failure to cause the identified
17 person(s) with that/those employer(s) to submit timely written acknowledgments to the Board
18 shall be considered a violation of probation.

19 "Employment" within the meaning of this provision includes any full-time, part-time,
20 temporary, relief, or employment/management service position as a pharmacist, or any position
21 for which a pharmacist is a requirement or criterion for employment, whether the Respondent is
22 an employee, independent contractor or volunteer.

23 **7. Notification of Change(s) in Name, Address(es), or Phone Number(s)**

24 Respondent shall further notify the Board in writing within ten (10) days of any change in
25 name, residence address, mailing address, e-mail address or phone number.

26 Failure to timely notify the Board of any change in employer, name, address, or phone
27 number shall be considered a violation of probation.

1 **8. Restrictions on Supervision and Oversight of Licensed Facilities**

2 During the period of probation, Respondent shall not supervise any intern pharmacist, be
3 the pharmacist-in-charge, designated representative-in-charge, responsible manager or other
4 compliance supervisor of any his licensed by the Board, nor serve as a consultant. Assumption of
5 any such unauthorized supervision responsibilities shall be considered a violation of probation.

6 **9. Reimbursement of Board Costs**

7 As a condition precedent to successful completion of probation, Respondent shall pay to the
8 Board its costs of investigation and prosecution in the amount of \$4,043. Respondent shall make
9 said payments as follows:

10 There shall be no deviation from this schedule absent prior written approval by the Board or
11 its designee. Failure to pay costs by the deadline(s) as directed shall be considered a violation of
12 probation.

13 Respondent shall be permitted to pay these costs in a payment plan approved by the Board
14 or its designee, so long as full payment is completed no later than one (1) year prior to the end
15 date of probation.

16 **10. Probation Monitoring Costs**

17 Respondent shall pay any costs associated with probation monitoring as determined by the
18 Board each and every year of probation. Such costs shall be payable to the Board on a schedule
19 as directed by the Board or its designee. Failure to pay such costs by the deadline(s) as directed
20 shall be considered a violation of probation.

21 **11. Status of License**

22 Respondent shall, at all times while on probation, maintain an active, current Pharmacist
23 License with the Board, including any period during which suspension or probation is tolled.
24 Failure to maintain an active, current Pharmacist License shall be considered a violation of
25 probation.

26 If Respondent's Pharmacist License expires or is cancelled by operation of law or otherwise
27 at any time during the period of probation, including any extensions thereof due to tolling or
28

otherwise, upon renewal or reapplication Respondent's license shall be subject to all terms and conditions of this probation not previously satisfied.

12. License Surrender While on Probation/Suspension

Following the effective date of this decision, should Respondent cease practice due to retirement or health, or be otherwise unable to satisfy the terms and conditions of probation, Respondent may relinquish his license, including any indicia of licensure issued by the Board, along with a request to surrender the license. The Board or its designee shall have the discretion whether to accept the surrender or take any other action it deems appropriate and reasonable. Upon formal acceptance of the surrender of the license, Respondent will no longer be subject to the terms and conditions of probation. This surrender constitutes a record of discipline and shall become a part of the Respondent's license history with the Board.

Upon acceptance of the surrender, Respondent shall relinquish his pocket and/or wall license, including any indicia of licensure not previously provided to the Board within ten (10) days of notification by the Board that the surrender is accepted if not already provided. Respondent may not reapply for any license from the Board for three (3) years from the effective date of the surrender. Respondent shall meet all requirements applicable to the license sought as of the date the application for that license is submitted to the Board, including any outstanding costs.

13. Practice Requirement – Extension of Probation

Except during periods of suspension, Respondent shall, at all times while on probation, be employed as a pharmacist in California for a minimum of 80 hours per calendar month. Any month during which this minimum is not met shall extend the period of probation by one month. During any such period of insufficient employment, Respondent must nonetheless comply with all terms and conditions of probation, unless Respondent receives a waiver in writing from the Board or its designee.

If Respondent does not practice as a pharmacist in California for the minimum number of hours in any calendar month, for any reason (including vacation), Respondent shall notify the Board in writing within ten (10) days of the conclusion of that calendar month. This notification

1 shall include at least: the date(s), location(s), and hours of last practice; the reason(s) for the
2 interruption or reduction in practice; and the anticipated date(s) on which Respondent will resume
3 practice at the required level. Respondent shall further notify the Board in writing within ten (10)
4 days following the next calendar month during which Respondent practices as a pharmacist in
5 California for the minimum of hours. Any failure to timely provide such notification(s) shall be
6 considered a violation of probation.

7 It is a violation of probation for Respondent's probation to be extended pursuant to the
8 provisions of this condition for a total period, counting consecutive and non-consecutive months,
9 exceeding thirty-six (36) months. The Board or its designee may post a notice of the extended
10 probation period on its website.

11 14. Violation of Probation

12 If Respondent has not complied with any term or condition of probation, the Board shall
13 have continuing jurisdiction over Respondent, and the Board shall provide notice to Respondent
14 that probation shall automatically be extended, until all terms and conditions have been satisfied
15 or the Board has taken other action as deemed appropriate to treat the failure to comply as a
16 violation of probation, to terminate probation, and to impose the penalty that was stayed. The
17 Board or its designee may post a notice of the extended probation period on its website.

18 If Respondent violates probation in any respect, the Board, after giving Respondent notice
19 and an opportunity to be heard, may revoke probation and carry out the disciplinary order that
20 was stayed. If a petition to revoke probation or an accusation is filed against Respondent during
21 probation, or the preparation of an accusation or petition to revoke probation is requested from
22 the Office of the Attorney General, the Board shall have continuing jurisdiction and the period of
23 probation shall be automatically extended until the petition to revoke probation or accusation is
24 heard and decided, and the charges and allegations in Accusation No. 6647 shall be deemed true
25 and correct.

26 ///

27 ///

28 ///

1 **15. Completion of Probation**

2 Upon written notice by the Board or its designee indicating successful completion of
3 probation, Respondent's license will be fully restored.

4 **16. Remedial Education**

5 Within sixty (60) days of the effective date of this decision, Respondent shall submit to the
6 Board or its designee, for prior approval, an appropriate program of remedial education related to
7 USP 797. The program of remedial education shall consist of at least fifteen (15) hours, which
8 shall be completed at Respondent's own expense. At least 50% of the total hours must be in
9 person or live webinar. All remedial education shall be in addition to, and shall not be credited
10 toward, continuing education (CE) courses used for license renewal purposes for pharmacists.

11 Failure to timely submit for approval or complete the approved remedial education shall be
12 considered a violation of probation. The period of probation will be automatically extended until
13 such remedial education is successfully completed and written proof, in a form acceptable to the
14 Board, is provided to the Board or its designee.

15 Following the completion of each course, the Board or its designee may require the
16 Respondent, at his own expense, to take an approved examination to test the Respondent's
17 knowledge of the course. If the Respondent does not achieve a passing score on the examination
18 that course shall not count towards satisfaction of this term. Respondent shall take another course
19 approved by the Board in the same subject area.

20 ///

21 ///

22 ///

23 ///

24 ///

25 ///

26 ///

27 ///

ACCEPTANCE

I have carefully read the above Stipulated Settlement and Disciplinary Order and have fully discussed it with my attorney, Luis Andre P. Vizcocho. I understand the stipulation and the effect it will have on my Pharmacy License. I enter into this Stipulated Settlement and Disciplinary Order voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order of the Board of Pharmacy.

DATED: 11/11/2020



AINSLIE HOI LI CHEUNG
Respondent

I have read and fully discussed with Respondent Ainslie Hoi Li Cheung the terms and conditions and other matters contained in the above Stipulated Settlement and Disciplinary Order. I approve its form and content.

DATED: _____

LUIS ANDRE P. VIZCOCHO
Attorney for Respondent

ENDORSEMENT

The foregoing Stipulated Settlement and Disciplinary Order is hereby respectfully submitted for consideration by the Board of Pharmacy.

DATED: _____

Respectfully submitted,

XAVIER BECERRA
Attorney General of California
ARMANDO ZAMBRANO
Supervising Deputy Attorney General

NANCY A. KAISER
Deputy Attorney General
Attorneys for Complainant

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 0
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 0
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8

2
3
4
5
6

8

9

$$\begin{matrix} 0 \\ 1 \\ 2 \end{matrix}$$

3

4

6

7
8

21
22

23

25

Exhibit A

Accusation No. 6647

1 XAVIER BECERRA
Attorney General of California
2 ARMANDO ZAMBRANO
Supervising Deputy Attorney General
3 NANCY A. KAISER
Deputy Attorney General
4 State Bar No. 192083
300 So. Spring Street, Suite 1702
5 Los Angeles, CA 90013
Telephone: (213) 269-6320
6 Facsimile: (213) 897-2804
Attorneys for Complainant
7

8 **BEFORE THE**
BOARD OF PHARMACY
9 **DEPARTMENT OF CONSUMER AFFAIRS**
10 **STATE OF CALIFORNIA**

11 In the Matter of the Accusation Against:

Case No. 6647

12 **SOUTHERN CALIFORNIA**
13 **HEALTHCARE SYSTEMS, INC.,**
14 **DBA SOUTHERN CALIFORNIA**
15 **HOSPITAL AT CULVER CITY,**
16 **DAVID TOPPER, C.E.O./DIRECTOR,**
17 **SAMUEL LEE, PRES./DIRECTOR,**
18 **WILLIAM MARC GORENSTEIN,**
19 **TREAS./C.F.O., ELLEN SHIN,**
20 **SECRETARY;**
21 **JILL CHANG, PHARMACIST-IN-**
22 **CHARGE (8/14/15-12/11/15, 3/2/16-8/31/17);**
23 **AINSLIE HOI LI CHEUNG,**
24 **PHARMACIST-IN-CHARGE (9/1/17-**
25 **2/27/18)**
26 **JACQUELINE HOANG VO,**
27 **PHARMACIST-IN-CHARGE (since 8/14/18)**
28 **3828 Delmas Terrace**
Culver City, CA 90232
Hospital Pharmacy Permit No. HSP 51172,

A C C U S A T I O N

22 **SOUTHERN CALIFORNIA**
23 **HEALTHCARE SYSTEMS, INC.,**
24 **DBA SOUTHERN CALIFORNIA**
25 **HOSPITAL AT CULVER CITY,**
26 **DAVID TOPPER, C.E.O./DIR., SAMUEL**
27 **LEE, PRES./DIR., WILLIAM MARC**
28 **GORENSTEIN, TREAS./C.F.O., ELLEN**
SHIN, SECRETARY
3828 Delmas Terrace
Culver City, CA 90232
Sterile Compounding Permit No. LSC
100222,

JILL CHANG
778 Flicker Ct.
Anaheim, CA 92807
Pharmacist License No. RPH 66782,

AINSLIE HOI LI CHEUNG
12837 Palisades Ct.
Poway, CA 92064
Pharmacist License No. RPH 64668,

and

JACQUELINE HOANG VO
15757 McIntosh Ave.
Chino, CA 91708
Pharmacist License No. RPH 45816

Respondents.

PARTIES

1. Anne Sodergren (Complainant) brings this Accusation solely in her official capacity as the Interim Executive Officer of the Board of Pharmacy, Department of Consumer Affairs.

2. On or about December 31, 2012, the Board of Pharmacy issued Hospital Pharmacy Permit Number HSP 51172 to Southern California Healthcare Systems, Inc., dba Southern California Hospital at Culver City, located at 3828 Delmas Terrace, Culver City, CA 90232 (Respondent Pharmacy). The Hospital Pharmacy Permit was in full force and effect at all times relevant to the charges brought herein and will expire on December 1, 2019, unless renewed. Since December 31, 2012, David Topper has been the Chief Executive Officer and Director, Samuel Lee has been the President and Director, and Ellen Shin has been the Secretary. Since March 15, 2016, William Marc Gorenstein has been the Treasurer/Chief Financial Officer. From August 14, 2015 to December 11, 2015 and March 2, 2016 to August 31, 2017 Jill Chang, RPH 66782, was the pharmacist-in-charge. From September 1, 2017, to February 27, 2018, Ainslie Hoi Li Cheung, RPH 64668, was the pharmacist-in-charge. February 28, 2018, and July 26, 2018, Christina Cao RPH 57888 was the pharmacist-in-charge. Since August 14, 2018, Jacqueline Hoang Vo has been the pharmacist-in-charge.

3. On or about May 29, 2014, the Board of Pharmacy issued Sterile Compounding Permit Number LSC 100222 to Southern California Healthcare Systems, Inc., dba Southern California Hospital at Culver City, David (Respondent Pharmacy). The Sterile Compounding Permit was in full force and effect at all times relevant to the charges brought herein and will expire on December 1, 2019, unless renewed.

4. On or about December 28, 2011, the Board of Pharmacy issued Pharmacist License Number RPH 66782 to Jill Chang (Respondent Chang). The Pharmacist License was in full force and effect at all times relevant to the charges brought herein and will expire on July 31, 2021, unless renewed.

5. On or about September 30, 2010, the Board of Pharmacy issued Pharmacist License Number RPH 64668 to Ainslie Hoi Li Cheung (Respondent Cheung). The Pharmacist License was in full force and effect at all times relevant to the charges brought herein and will expire on December 31, 2019, unless renewed.

6. On or about September 22, 1992, the Board of Pharmacy issued Pharmacist License Number RPH 45816 to Jacqueline Hoang Vo (Respondent Vo). The Pharmacist License was in full force and effect at all times relevant to the charges brought herein and will expire on March 31, 2020, unless renewed.

JURISDICTION

7. This Accusation is brought before the Board of Pharmacy (Board), Department of Consumer Affairs, under the authority of the following laws. All section references are to the Business and Professions Code unless otherwise indicated.

8. Section 4300 provides in pertinent part, that every license issued by the Board is subject to discipline, including suspension or revocation.

///

///

///

1 9. Section 4300.1 of the Code states:

2 "The expiration, cancellation, forfeiture, or suspension of a board-issued license
3 by operation of law or by order or decision of the board or a court of law, the
4 placement of a license on a retired status, or the voluntary surrender of a license
5 by a licensee shall not deprive the board of jurisdiction to commence or proceed
6 with any investigation of, or action or disciplinary proceeding against, the
7 licensee or to render a decision suspending or revoking the license."

8 10. Section 4113, subdivision (c), states that "[t]he pharmacist-in-charge shall be
9 responsible for a pharmacy's compliance with all state and federal laws and regulations
10 pertaining to the practice of pharmacy."

11 11. Section 4022 of the Code states:

12 "‘Dangerous drug’ or ‘dangerous device’ means any drug or device unsafe for
13 self-use in humans or animals, and includes the following:

14 (a) Any drug that bears the legend: ‘Caution: federal law prohibits dispensing without
15 prescription,’ ‘Rx only,’ or words of similar import.

16 (b) Any device that bears the statement: "Caution: federal law restricts this device to
17 sale by or on the order of a _____," "Rx only," or words of similar import, the
18 blank to be filled in with the designation of the practitioner licensed to use or order use
19 of the device.

20 (c) Any other drug or device that by federal or state law can be lawfully dispensed
21 only on prescription or furnished pursuant to Section 4006."

22 12. Section 4033 of the Code states, in part:

23 "(a)(1) ‘Manufacturer’ means and includes every person who prepares, derives,
24 produces, compounds, or repackages any drug or device except a pharmacy that
25 manufactures on the immediate premises where the drug or device is sold to the
26 ultimate consumer."

27 13. Section 4301 of the Code states, in part:

28 "The board shall take action against any holder of a license who is guilty of
unprofessional conduct or whose license has been issued by mistake.
Unprofessional conduct shall include, but is not limited to, any of the
following:

· · ·
29 "(c) Gross negligence.

· · ·
30 "(j) The violation of any of the statutes of this state, of any other state, or of the
31 United States regulating controlled substances and dangerous drugs.

· · ·
32 "(o) Violating or attempting to violate, directly or indirectly, or assisting in or
33 abetting the violation of or conspiring to violate any provision or term of this
34 chapter or of the applicable federal and state laws and regulations governing

pharmacy, including regulations established by the board or by any other state or federal regulatory agency.”

14. Section 4306.5 of the Code states, in part:

“Unprofessional conduct for a pharmacist may include any of the following:

"(a) Acts or omissions that involve, in whole or in part, the inappropriate exercise of his or her education, training, or experience as a pharmacist, whether or not the act or omission arises in the course of the practice of pharmacy or the ownership, management, administration, or operation of a pharmacy or other entity licensed by the board.

"(b) Acts or omissions that involve, in whole or in part, the failure to exercise or implement his or her best professional judgment or corresponding responsibility with regard to the dispensing or furnishing of controlled substances, dangerous drugs, or dangerous devices, or with regard to the provision of services.”

15. Section 4307, subdivision (a), of the Code states:

“(a) Any person who has been denied a license or whose license has been revoked or is under suspension, or who has failed to renew his or her license while it was under suspension, or who has been a manager, administrator, owner, member, officer, director, associate, partner, or any other person with management or control of any partnership, corporation, trust, firm, or association whose application for a license has been denied or revoked, is under suspension or has been placed on probation, and while acting as the manager, administrator, owner, member, officer, director, associate, partner, or any other person with management or control had knowledge of or knowingly participated in any conduct for which the license was denied, revoked, suspended, or placed on probation, shall be prohibited from serving as a manager, administrator, owner, member, officer, director, associate, partner, or in any other position with management or control of a licensee as follows:

(1) Where a probationary license is issued or where an existing license is placed on probation, this prohibition shall remain in effect for a period not to exceed five years.

(2) Where the license is denied or revoked, the prohibition shall continue until the license is issued or reinstated.

(b) Manager, administrator, owner, member, officer, director, associate, partner, or any other person with management or control of a license as used in this section and Section 4308, may refer to a pharmacist or to any other person who serves in such capacity in or for a licensee.

(c) The provisions of subdivision (a) may be alleged in any pleading filed pursuant to Chapter 5 (commencing with Section 11500) of Part 1 of Division 3 of the Government Code. However, no order may be issued in that case except as to a person who is named in the caption, as to whom the pleading alleges the applicability of this section, and where the person has been given notice of the proceeding as required by Chapter 5 (commencing with Section 11500) of Part 1 of Division 3 of the Government Code. The authority to proceed as provided by this subdivision shall be in addition to the board’s authority to proceed under Section 4339 or any other provision of law.”

16. Section 4169 of the Code states, in part:

“(a) A person or entity shall not do any of the following:

...
(2) Purchase, trade, sell, or transfer dangerous drugs that the person knew or reasonably should have known were adulterated, as set forth in Article 2 (commencing with Section 111250) of Chapter 6 of Part 5 of Division 104 of the Health and Safety Code.”

REGULATORY PROVISIONS

17. California Code of Regulations, title 16, section 1715 states in pertinent part:

“(a) The pharmacist-in-charge of each pharmacy as defined under section 4029 or section 4037 of the Business and Professions Code shall complete a self-assessment of the pharmacy's compliance with federal and state pharmacy law. The assessment shall be performed before July 1 of every odd-numbered year. The primary purpose of the self-assessment is to promote compliance through self-examination and education.

“(b) In addition to the self-assessment required in subdivision (a) of this section, the pharmacist-in-charge shall complete a self-assessment within 30 days whenever: . . .

(2) There is a change in the pharmacist-in-charge, and he or she becomes the new pharmacist-in-charge of a pharmacy.”

18. California Code of Regulations, title 16, section 1735.2, states, in pertinent part:

“(e)(3) A drug preparation shall not be compounded until the pharmacy has first prepared a written master formula document that includes at least the following elements: . . . (3) The maximum allowable beyond use date for the preparation, and the rationale or reference source justifying its determination.

...
“(g) The pharmacist performing or supervising compounding is responsible for the integrity, potency, quality, and labeled strength of a compounded drug preparation until the beyond use date indicated on the label, so long as label instructions for storage and handling are followed after the preparation is dispensed.

...
“(k) Prior to allowing any drug product preparation to be compounded in a pharmacy, the pharmacist-in-charge shall complete a self-assessment for compounding pharmacies developed by the board (Incorporated by reference is "Community Pharmacy & Hospital Outpatient Pharmacy Compounding Self-Assessment" Form 17M-39 Rev. 02/12.) as required by Section 1715 of Title 16, Division 17, of the California Code of Regulations. That form contains a first section applicable to all compounding, and a second section applicable to sterile injectable compounding. The first section must be completed by the pharmacist-in-charge before any compounding is performed in the pharmacy. The second section must be completed by the pharmacist-in-charge before any sterile compounding is performed in the pharmacy. The applicable sections of the self-assessment shall subsequently be completed before July 1 of each odd-numbered year, within 30 days of the start date of a new

1 pharmacist-in-charge or change of location, and within 30 days of the issuance of a
2 new pharmacy license. The primary purpose of the self-assessment is to promote
compliance through self-examination and education.”

3 19. California Code of Regulations, title 16, section 1735.4(a)(5) states:

4 “(a) Each compounded drug preparation shall be affixed with a container label prior
5 to dispensing that contains at least: . . . (5) The date compounded.”

6 20. California Code of Regulations, title 16, section 1735.8(b) states:

7 “The quality assurance plan shall include written procedures for verification,
8 monitoring, and review of the adequacy of the compounding processes and shall also
9 include written documentation of review of those processes by qualified pharmacy
personnel.”

10 21. California Code of Regulations, title 16, section 1751.3 states, in part:

11 “(a) Any pharmacy engaged in compounding sterile drug preparations shall maintain
12 written policies and procedures for compounding. Any material failure to follow the
13 pharmacy's written policies and procedures shall constitute a basis for disciplinary
action. In addition to the elements required by section 1735.5, there shall be written
policies and procedures regarding the following:

14 (1) Action levels for colony-forming units (CFUs) detected during viable surface
15 sampling, glove fingertip, and viable air sampling and actions to be taken when the
levels are exceeded.”

16 22. California Code of Regulations, title 16, section 1751.4(a) states:

17 “No sterile drug preparation shall be compounded if it is known, or reasonably should
18 be known, that the compounding environment fails to meet criteria specified in the
19 pharmacy's written policies and procedures for the safe compounding of sterile drug
preparations.”

20 23. California Code of Regulations, title 16, section 1751.8(e) states:

21 “Where any sterile compounded drug preparation was compounded either outside of
22 an ISO class 5 PEC or under conditions that do not meet all of the requirements for
any of subdivisions (a) through (d), the sterile compounded drug preparation shall be
23 labeled for "immediate use only" and administration shall begin no later than one hour
24 following the start of the compounding process. Unless the "immediate
use" preparation is immediately and completely administered by the person who
25 prepared it or immediate and complete administration is witnessed by the preparer,
the preparation shall bear a label listing patient identification information, the names
26 and amounts of all ingredients, the name or initials of the person who prepared the
compounded sterile preparation, and the exact one-hour beyond use date and time. If
27 administration has not begun within one hour following the start of the compounding
process, the compounded sterile preparation shall be promptly, properly, entirely, and
28 safely discarded. This provision does not preclude the use of a PEC to compound an

1 "immediate use" preparation. A PEC used solely to compound 'immediate use'
2 preparations need not be placed within an ISO Class 7 cleanroom, with an ante-area.
3 Such "immediate use" preparations shall be compounded only in those limited
4 situations where there is a need for immediate administration of a sterile preparation
5 compounded outside of an ISO class 5 environment and where failure to administer
6 could result in loss of life or intense suffering. Any such compounding shall be only
7 in such quantity as is necessary to meet the immediate need and the circumstance
8 causing the immediate need shall be documented in accordance with policies and
9 procedures."

10 **HEALTH AND SAFETY CODE**

11 24. Health & Safety Code section 111250 states: "Any drug or device is adulterated
12 if it consists, in whole or in part, of any filthy, putrid, or decomposed substance."

13 25. Health & Safety Code section 111295 states: "It is unlawful for any person to
14 manufacture, sell, deliver, hold, or offer for sale any drug or device that is adulterated."

15 **COST RECOVERY**

16 26. Section 125.3 of the Code provides, in pertinent part, that the Board may
17 request the administrative law judge to direct a licentiate found to have committed a
18 violation or violations of the licensing act to pay a sum not to exceed the reasonable costs of
19 the investigation and enforcement of the case, with failure of the licentiate to comply
20 subjecting the license to not being renewed or reinstated. If a case settles, recovery of
21 investigation and enforcement costs may be included in a stipulated settlement.

22 **FACTUAL SUMMARY**

23 27. Respondent Pharmacy is an inpatient hospital pharmacy within Southern
24 California Hospital at Culver City, a community hospital, located at 3828 Delmas Terrace,
25 Culver City, California. The hospital is licensed for 450 general acute care beds by the
26 California Department of Public Health (CDPH).

27 **2017 Inspection**

28 28. On or about November 21, 2017, a Board inspector performed a routine sterile
compounding license renewal inspection of Respondent Pharmacy's facility, which revealed
the following.

29 29. Respondent Pharmacy was performing sterile-to-sterile compounding and
preparing low to medium risk compounded sterile preparations (CSPs), such as intravenous

1 antibiotics, electrolyte infusions, and total parenteral nutrition. The pharmacy prepared on
2 average approximately 80 CSPs daily.

3 30. The pharmacy had one ISO Class 5 compounding aseptic isolator (CAI). CAIs
4 are composed of two chambers: the main chamber, where sterile compounding takes place,
5 and the purge/airlock chamber, where material transfer occurs. The purge/airlock chamber
6 ensures that the main chamber remains at least ISO Class 5 during insertion and removal of
7 items. Both chambers should maintain an ISO 5 or better environment for compounding
8 sterile preparations. Respondent Pharmacy hired Clean Air Services (CAS), an outside
9 company, to perform the environmental testing for its CAI every six months.

10 31. On February 25, 2017, CAS performed an environmental sampling test of
11 Respondent Pharmacy's CAI. The CAI failed the test, in that the test results indicated that
12 nine (9) CFUs of fungal air growth were inside the ISO 5 CAI airlock chamber. On March
13 10, 2017, the test results were reported to Respondent Pharmacy, yet the re-testing of the
14 CAI for viable growth was not performed until May 4, 2017.

15 32. On May 4, 2017, Respondent Pharmacy's CAI failed the environmental
16 sampling test again, as it continued to show fungal air growth inside the CAI. Specifically,
17 the test results indicated that three (3) CFUs of fungal air growth were inside the ISO 5 CAI
18 airlock chamber. On May 22, 2017, these results were reported to Respondent Pharmacy,
19 yet the re-testing of the CAI for viable growth was not performed until August 15, 2017.

20 33. On August 15, 2017, Respondent Pharmacy's CAI failed the environmental
21 sampling test again, in that five (5) CFUs (fungal organisms) were identified on the air
22 samples inside the purge/airlock chamber of the ISO 5 CAI and three (3) CFUs (fungal
23 organisms) were identified on the air samples inside the main chamber of the ISO 5 CAI. In
24 addition, six (6) CFUs (bacterial organisms) were identified on the air samples inside the
25 purge/airlock chamber of the ISO 5 CAI, and two (2) CFUs (bacterial organisms) were
26 identified on the air samples inside the main chamber of the ISO 5 CAI.

27 34. On September 18, 2017, Respondent Pharmacy's CAI was retested and failed
28 the environmental sampling test again. The report, dated September 26, 2017, showed that

1 two (2) CFUs were found in viable air samples inside the airlock chamber of the ISO 5 CAI.
2 The result was listed as “Fail” and the reason for fail result stated, “Total CFU result
3 exceeds action level concentration and actionable microorganism/s detected.” Actionable
4 microorganisms were identified in the report as “Gram-negative bacteria, coagulase-positive
5 Staphylococcus, molds and yeasts.”

6 35. From at least February 25, 2017, until at least November 22, 2017, Respondent
7 Pharmacy prepared CSPs inside the ISO 5 CAI, without first assuring the CAI was free
8 from microbial contamination. Since the pharmacy prepared on average about 80 CSPs
9 daily, it means an estimated number of 21,000 possibly contaminated CSP units were
10 prepared and dispensed to patients of Southern California Hospital at Culver City in this
11 time frame.

12 36. Respondent Pharmacy’s policies and procedures state, in part:

13 “Viable air sampling shall be done by volumetric air sampling procedures which test a
14 sufficient volume of air (400 to 1,000 liters) inside of CAI and shall be done at least once
15 every six months. It shall be performed by qualified individual who is familiar with the
16 methods and procedures. When the environmental monitoring action levels are exceeded,
17 the pharmacy shall identify the CFUs at least to the genus level in addition to conducting an
18 investigation. Remediation shall include, at minimum, an immediate investigation of
19 cleaning and compounding operation and facility management”.

20 37. Respondent Pharmacy’s policies and procedures do not address action levels for
21 CFUs detected during viable surface and air sampling and actions to take when the levels
22 are exceeded.

23 38. Respondent Pharmacy’s policies and procedures also state:

24 “A batched-produced low to medium risk CSP shall be subject to documented end
25 product quantitative analysis once a year. The analysis will be conducted by a laboratory.”
26 One CSP prepared at the pharmacy was tested for potency on September 14, 2016, by an
27 outside lab. On October 10, 2017, another CSP was sent out for testing. October 10, 2017,
28 is more than one year after its CSP potency testing performed on September 14, 2016.

39. During the Board’s inspection on November 21, 2017, several CSP labels and master formulas for compounded sterile preparations were reviewed. None of the CSP labels reviewed contained the date the CSP was compounded, and none of the master formula documents reviewed included the rationale or reference source justifying their determination of the maximum allowable beyond-use-date (expiration date) for CSPs.

40. The 2017 USP 797¹ guidelines state, in part:

“Any CFU² count that exceeds its respective action level should prompt a re-evaluation of the adequacy of personnel work practices, cleaning procedures, operational procedures, and air filtration efficiency within the aseptic compounding location. An investigation into the source of the contamination shall be conducted. Sources could include HVAC systems, damaged HEPA filters, and changes in personnel garbing or work practices. The source of the problem shall be eliminated, the affected area cleaned, and resampling performed. . . . Highly pathogenic microorganisms (e.g., Gram-negative rods, coagulase positive staphylococcus, molds and yeasts) can be potentially fatal to patients receiving CSPs and must be immediately remedied, regardless of CFU count, with the assistance of a competent microbiologist, infection control professional, or industrial hygienist.”

41. For ISO Class 5, the 2017 USP 797 guidelines' recommended action level for microbial contamination is more than one (1) CFU.

2018 Inspection

42. On or about October 11, 2018, a Board inspector performed a routine sterile compounding license renewal inspection of Respondent Pharmacy's facility, which revealed the following.

¹ USP 797 refers to chapter 797 "Pharmaceutical Compounding – Sterile Preparations," in the USP National Formulary. It is the first set of enforceable sterile compounding standards issued by the United States Pharmacopeia (USP).

² In microbiology, a colony-forming unit (CFU) is a unit used to measure the number of viable bacteria or fungal cells in a sample. Viable is defined as the ability to multiply.

1 43. On July 28, 2018, Respondent Pharmacy implemented its decision to
2 decommission the use of the compounding aseptic isolator (CAI) and begin making the
3 compounded sterile drug preparations (CSPs), previously made in the CAI, on the counter
4 located in the segregated compounding area, as immediate-use CSPs with a beyond use date
5 (BUD) of one (1) hour.

6 44. Between July 28, 2018, and October 9, 2018, Respondent Pharmacy
7 compounded at least 200 banana bags each of which contained at least 3 additives, as
8 immediate-use preparations, where there was no need for immediate administration of a
9 sterile preparation compounded outside of an ISO class 5 environment and where failure to
10 administer could not result in loss of life or intense suffering, and did not document the
11 circumstance causing the need. Between August 14, 2018, and October 9, 2018, while
12 Respondent Vo was the pharmacist-in-charge and responsible for pharmacy operations,
13 Respondent Pharmacy compounded at least 150 of these banana bags.

14 **FIRST CAUSE FOR DISCIPLINE**

15 **(Failure to Comply with Required Sterile Compounding Policies and Procedures)**

16 45. Respondents Pharmacy, Chang, and Cheung are subject to disciplinary action
17 under section 4301, subdivision (o), on the grounds of unprofessional conduct, in that they
18 failed to comply with California Code of Regulations, title 16, section 1751.3(a)(1).
19 Specifically, while Respondents Chang and Cheung served as the pharmacist-in-charge,
20 respectively, Respondent Pharmacy did not maintain written policies and procedures that
21 addressed action levels for CFUs detected during viable surface and air sampling and
22 actions to be taken when the CFU levels are exceeded. Complainant refers to, and by this
23 reference incorporates, the allegations set forth in paragraphs 28 through 41, above, as
24 though set forth fully herein.

25 **SECOND CAUSE FOR DISCIPLINE**

26 **(Failure to Comply with Facility and Equipment Standards for Sterile Compounding)**

27 46. Respondents Pharmacy, Chang, and Cheung are subject to disciplinary action
28 under section 4301, subdivision (o), on the grounds of unprofessional conduct, in that they

1 failed to comply with California Code of Regulations, title 16, section 1751.4(a).
2 Specifically, while Respondents Chang and Cheung served as the pharmacist-in-charge,
3 respectively, Respondent Pharmacy's policy and procedures stated, "When the
4 environmental monitoring action levels are exceeded; the pharmacy shall identify the CFUs
5 at least to the genus level in addition to conducting an investigation. Remediation shall
6 include, at minimum, an immediate investigation of cleaning and compounding operation
7 and facility management." The pharmacy failed to conduct an immediate investigation, as
8 described in their policy, when the environmental monitoring action levels were exceeded
9 on viable testing on May 4, 2017, and September 18, 2017. The pharmacy, therefore,
10 compounded sterile drug preparations in the compounding environment that failed to meet
11 criteria specified in the pharmacy's written policies and procedures for the safe
12 compounding of sterile drug preparations. Complainant refers to, and by this reference
13 incorporates, the allegations set forth in paragraphs 28 through 41, above, as though set
14 forth fully herein.

15 **THIRD CAUSE FOR DISCIPLINE**

16 **(Delivering Adulterated Medications)**

17 47. Respondents Pharmacy, Chang, and Cheung are subject to disciplinary action
18 under section 4301, subdivision (o), on the grounds of unprofessional conduct, in that they
19 failed to comply with section 4169(a)(2) of the Code and Health and Safety Code sections
20 111250 and 111295. Specifically, from at least February 25, 2017, until at least November
21 22, 2017, the pharmacy delivered approximately 21,000 units of adulterated dangerous
22 drugs to patients of Southern California Hospital at Culver City. From at least February 25,
23 2017, until at least August 31, 2017, while Respondent Chang served as the pharmacist-in-
24 charge, the pharmacy delivered approximately 15,000 units of adulterated dangerous drugs
25 to patients of Southern California Hospital at Culver City. From at least September 1, 2017,
26 until at least November 22, 2017, while Respondent Cheung served as the pharmacist-in-
27 charge, Respondent Pharmacy delivered approximately 6,000 units of adulterated dangerous
28 drugs to patients of Southern California Hospital at Culver City. Complainant refers to, and

1 by this reference incorporates, the allegations set forth in paragraphs 28 through 41, above,
2 as though set forth fully herein.

3 **FOURTH CAUSE FOR DISCIPLINE**

4 **(Gross Negligence)**

5 48. Respondent Pharmacy is subject to disciplinary action under section 4301,
6 subdivision (c), in that it committed gross negligence. Specifically, from at least February
7 25, 2017, until at least November 22, 2017, Respondent Pharmacy was grossly negligent in
8 properly addressing repetitive microbial air contamination of the ISO 5 CAI, where sterile
9 compounding took place. Complainant refers to, and by this reference incorporates, the
10 allegations set forth in paragraphs 28 through 41, above, as though set forth fully herein.

11 **FIFTH CAUSE FOR DISCIPLINE**

12 **(Failure to Comply with Compounding Quality Assurance Requirements)**

13 49. Respondents Pharmacy and Cheung are subject to disciplinary action under
14 section 4301, subdivision (o), on the grounds of unprofessional conduct, in that they failed
15 to comply with California Code of Regulations, title 16, section 1735.8(b). Specifically,
16 while Respondent Cheung was serving as the pharmacist-in-charge, Respondent Pharmacy's
17 CSP potency testing performed on October 10, 2017, was more than one year after CSP
18 potency testing performed on September 14, 2016, and, therefore, was not conducted on at
19 least an annual basis. Complainant refers to, and by this reference incorporates, the
20 allegations set forth in paragraphs 28 through 41, above, as though set forth fully herein.

21 **SIXTH CAUSE FOR DISCIPLINE**

22 **(Failure to Comply with Labeling Requirements)**

23 50. Respondents Pharmacy and Cheung are subject to disciplinary action under
24 section 4301, subdivision (o), on the grounds of unprofessional conduct, in that they failed
25 to comply with California Code of Regulations, title 16, section 1735.4(a)(5). Specifically,
26 while Respondent Cheung was serving as the pharmacist-in-charge, CSP labels reviewed on
27 the Board's November 21, 2017, inspection did not contain the date compounded.
28

1 Complainant refers to, and by this reference incorporates, the allegations set forth in
2 paragraphs 28 through 41, above, as though set forth fully herein.

3 **SEVENTH CAUSE FOR DISCIPLINE**

4 **(Failure to Comply with Compounding Limitations and Requirements)**

5 51. Respondents Pharmacy and Cheung are subject to disciplinary action under
6 section 4301, subdivision (o), on the grounds of unprofessional conduct, in that they failed
7 to comply with California Code of Regulations, title 16, section 1735.2(e)(3). Specifically,
8 while Respondent Cheung was serving as the pharmacist-in-charge, master formula
9 documents for CSPs reviewed during the Board's November 21, 2017, inspection did not
10 include the rationale or reference sources justifying the maximum allowable beyond use
11 date for the preparations. Complainant refers to, and by this reference incorporates, the
12 allegations set forth in paragraphs 28 through 41, above, as though set forth fully herein.

13 **EIGHTH CAUSE FOR DISCIPLINE**

14 **(Inappropriate Exercise of Education,
15 Training, or Experience as a Pharmacist)**

16 52. Respondents Cheung and Chang are subject to disciplinary action under Code
17 section 4301, subdivisions (j) and (o), on the grounds of unprofessional conduct, as defined
18 in Code section 4306.5, subdivision (a), in that they inappropriately exercised their
19 respective education, training, and experience as a pharmacist in the course of the practice
20 of pharmacy and operation of a pharmacy. Complainant refers to, and by this reference
21 incorporates, the allegations set forth in paragraphs 28 through 41, above, as though set
22 forth fully herein.

23 **NINTH CAUSE FOR DISCIPLINE**

24 **(Failure to Exercise Professional Judgment)**

25 53. Respondents Cheung and Chang are subject to disciplinary action under Code
26 section 4301, subdivisions (j) and (o), on the grounds of unprofessional conduct, as defined
27 in Code section 4306.5, subdivision (b), in that they failed to exercise and implement their
28 best professional judgment when dispensing dangerous drugs. Complainant refers to, and by

1 this reference incorporates, the allegations set forth in paragraphs 28 through 41, above, as
2 though set forth fully herein.

3 **TENTH CAUSE FOR DISCIPLINE**

4 **(Failure to comply with Self-Assessment of a Pharmacy Requirement)**

5 54. Respondents Pharmacy and Vo are subject to disciplinary action under Code
6 section 4301, subdivision (o), on the grounds of unprofessional conduct, in that they failed
7 to comply with California Code of Regulations, title 16, section 1715(a) and (b)(2).
8 Respondents Pharmacy and Vo failed to promote compliance through self-examination and
9 education when Respondent Vo associated as the pharmacist-in-charge, effective August 14,
10 2018, and failed to complete a self-assessment of the pharmacy's compliance with federal
11 and state pharmacy law until October 12, 2018. Complainant refers to, and by this reference
12 incorporates, the allegations set forth in paragraphs 42 through 44, above, as though set
13 forth fully herein.

14 **ELEVENTH CAUSE FOR DISCIPLINE**

15 **(Failure to Complete Compounding Self-Assessment)**

16 55. Respondents Pharmacy and Vo are subject to disciplinary action under Code
17 section 4301, subdivision (o), on the grounds of unprofessional conduct, in that they failed
18 to comply with California Code of Regulations, title 16, section 1735.2(k). Specifically,
19 between September 15, 2018, and October 9, 2018, while Respondent Vo served as the
20 pharmacist-in-charge, Respondent Pharmacy compounded at least 900 compounded drug
21 preparations without Respondent Vo having completed a self-assessment for compounding
22 pharmacies within 30 days of associating as the pharmacist-in-charge. Complainant refers
23 to, and by this reference incorporates, the allegations set forth in paragraphs 42 to 44, above,
24 as though set forth fully herein.

25 **TWELFTH CAUSE FOR DISCIPLINE**

26 **(Failure to Comply with Immediate Use Compounding Requirements)**

27 56. Respondents Pharmacy and Vo are subject to disciplinary action under Code
28 section 4301, subdivision (o), on the grounds of unprofessional conduct, in that they failed

1 to comply with California Code of Regulations, title 16, section 1735.2(g). Specifically,
2 between July 28, 2018, and October 9, 2018, Respondent Pharmacy compounded at least
3 200 banana bags, each of which contained at least 3 additives, as immediate-use
4 preparations, where there was no need for immediate administration of a sterile preparation
5 compounded outside of an ISO class 5 environment and where failure to administer could
6 not result in loss of life or intense suffering, and did not document the circumstance causing
7 the need. Between August 14, 2018, and October 9, 2018, while Respondent Vo served as
8 the pharmacist-in-charge and was responsible for pharmacy operations, Respondent
9 Pharmacy compounded at least 150 of these banana bags. Complainant refers to, and by
10 this reference incorporates, the allegations set forth in paragraphs 42 to 44, above, as though
11 set forth fully herein.

12 **THIRTEENTH CAUSE FOR DISCIPLINE**

13 **(Failure to Follow Pharmacy's Policies and Procedures)**

14 57. Respondents Pharmacy and Vo are subject to disciplinary action under Code
15 section 4301, subdivision (o), on the grounds of unprofessional conduct, in that they failed
16 to comply with California Code of Regulations, title 16, section 1751.3 subdivision (a).
17 Specifically, between July 28, 2018, and October 9, 2018, Respondent Pharmacy failed to
18 follow its written policies and procedures, which stated "Preparations that are medium-risk
19 level and high-risk level CSPs shall not be prepared as immediate-use CSPs", by
20 compounding at least 200 medium-risk CSPs as immediate use. Between August 14, 2018,
21 and October 9, 2018, while Respondent Vo served as the pharmacist-in-charge and was
22 responsible for pharmacy operations, Respondent Pharmacy failed to follow its written
23 policies and procedures, which stated "Preparations that are medium-risk level and high-risk
24 level CSPs shall not be prepared as immediate-use CSPs", by compounding at least 150 of
25 these banana bags. Complainant refers to, and by this reference incorporates, the allegations
26 set forth in paragraphs 42 to 44, above, as though set forth fully herein.

27 ///

28 ///

1 **FOURTEENTH CAUSE FOR DISCIPLINE**

2 **(Inappropriate Exercise of Education,**
3 **Training, or Experience as a Pharmacist)**

4 58. Respondent Vo is subject to disciplinary action under Code section 4301,
5 subdivision (o), on the grounds of unprofessional conduct, for violating section 4306.5
6 subdivision (a). Specifically, between August 14, 2018, and October 9, 2018, while
7 Respondent Vo served as the pharmacist-in-charge and was responsible for pharmacy
8 operations for Respondent Pharmacy, she failed to exercise her education, training,
9 experience and best professional judgment when Respondent Pharmacy dispensed at least
10 150 medium-risk level CSPs as “immediate-use”. Complainant refers to, and by this
11 reference incorporates, the allegations set forth in paragraphs 42 to 44, above, as though set
12 forth fully herein.

13 **FIFTEENTH CAUSE FOR DISCIPLINE**

14 **(Failure to Exercise Professional Judgment)**

15 51. Respondent Vo is subject to disciplinary action under Code section 4301,
16 subdivisions (j) and (o), on the grounds of unprofessional conduct, as defined in Code
17 section 4306.5, subdivision (b). Specifically, while serving as the pharmacist-in-charge,
18 Respondent Vo failed to exercise and implement her best professional judgment when
19 Respondent Pharmacy dispensed at least 150 medium-risk level CSPs as “immediate-use”.
20 Complainant refers to, and by this reference incorporates, the allegations set forth in
21 paragraphs 42 to 44, above, as though set forth fully herein.

22 **OTHER MATTERS**

23 59. Pursuant to Code section 4307, if discipline is imposed on Hospital
24 Pharmacy Permit Number HSP 51172 issued to Southern California Healthcare Systems,
25 Inc., dba Southern California Hospital at Culver City, Southern California Healthcare
26 Systems, Inc. shall be prohibited from serving as a manager, administrator, owner, member,
27 officer, director, associate, or partner of a licensee for five years if Hospital Pharmacy
28

Permit Number HSP 51172 is placed on probation or until Hospital Pharmacy Permit Number HSP 51172 is reinstated if it is revoked.

60. Pursuant to Code section 4307, if discipline is imposed on Hospital Pharmacy Permit Number HSP 51172 issued to Southern California Healthcare Systems, Inc., dba Southern California Hospital at Culver City while David Topper, C.E.O./Director, Samuel Lee, Pres./Director, William Marc Gorenstein, Treas./C.F.O., and/or Ellen Shin, Secretary, as applicable, has been an officer and had knowledge of or knowingly participated in any conduct for which the licensee was disciplined, David Topper, C.E.O./Director, Samuel Lee, Pres./Director, William Marc Gorenstein, Treas./C.F.O., or Ellen Shin, Secretary, as applicable, shall be prohibited from serving as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee for five years if Hospital Pharmacy Permit Number HSP 51172 is placed on probation or until Hospital Pharmacy Permit Number HSP 51172 is reinstated if it is revoked.

PRAYER

WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged, and that following the hearing, the Board of Pharmacy issue a decision:

1. Revoking or suspending Hospital Pharmacy Permit Number HSP 51172, issued to Southern California Healthcare Systems, Inc., dba Southern California Hospital at Culver City, David;

2. Revoking or suspending Sterile Compounding Permit Number LSC 100222, issued to Southern California Healthcare Systems, Inc., dba Southern California Hospital at Culver City, David;

3. Revoking or suspending Pharmacist License Number RPH 66782, issued to Jill Chang;

4. Revoking or suspending Pharmacist License Number RPH 64668, issued to Ainslie Hoi Li Cheung;

5. Revoking or suspending Pharmacist License Number RPH 45816, issued to
Jacqueline Hoang Vo;

1 6. Prohibiting Southern California Healthcare Systems, Inc., from serving as a
2 manager, administrator, owner, member, officer, director, associate, or partner of a licensee
3 for five years if Hospital Pharmacy Permit Number HSP 51172 is placed on probation or
4 until Hospital Pharmacy Permit Number HSP 51172 is reinstated if Hospital Pharmacy
5 Permit No. HSP 51172 issued to Southern California Healthcare Systems, Inc., dba
6 Southern California Hospital at Culver City is revoked;

7 7. Prohibiting David Topper, C.E.O./Director, Samuel Lee, Pres./Director,
8 William Marc Gorenstein, Treas./C.F.O., and/or Ellen Shin, Secretary, as applicable, from
9 serving as a manager, administrator, owner, member, officer, director, associate, or partner
10 of a licensee for five years if Hospital Pharmacy Permit Number HSP 51172 is placed on
11 probation or until Hospital Pharmacy Permit Number HSP 51172 is reinstated if Hospital
12 Pharmacy Permit Number HSP 51172 issued to Southern California Healthcare Systems,
13 Inc., dba Southern California Hospital at Culver City is revoked;

14 8. Ordering Southern California Healthcare Systems, Inc., dba Southern California
15 Hospital at Culver City, Jill Chang, Ainslie Hoi Li Cheung, and Jacqueline Hoang Vo to
16 pay the Board of Pharmacy the reasonable costs of the investigation and enforcement of this
17 case, pursuant to Business and Professions Code section 125.3; and,

18 9. Taking such other and further action as deemed necessary and proper.
19
20

21 DATED: September 10, 2019
22



23 ANNE SODERGREN
24 Interim Executive Officer
25 Board of Pharmacy
26 Department of Consumer Affairs
27 State of California
28 Complainant

LA2019500573
53328603_2